Opens in a new tab or window SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body ...

Tirzepatide became the subject of national debate recently when the UK government announced plans to roll it out to ...

The average 15.4%-22.9% weight losses across the tirzepatide doses achieved initially in the trial were maintained throughout ...

Novo Nordisk said on Friday its weight-loss drug met the main goals of a late-stage trial in patients with a type of fatty ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

This implies monthly maintenance doses, which would give it a big leg up on tirzepatide and semaglutide, which require weekly ...

Dumb Blonde” podcast host Bunnie Xo shared that she’s lost 4 lbs. on the weight-loss drug Tirzepatide and is now “pooping ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report), retaining the price ...